Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Progesterone Receptors. Found 16 abstracts

Winn JS, Baker MG, Fanous IS, Slack-Davis JK, Atkins KA, Dillon PM. Lobular Breast Cancer and Abdominal Metastases: A Retrospective Review and Impact on Survival. Oncology. 2016 Jan;91(3):135-42.
Camacho-Rivera M, Ragin C, Roach V, Kalwar T, Taioli E. Breast cancer clinical characteristics and outcomes in Trinidad and Tobago. Journal of immigrant and minority health. 2015 Jun;17(3):765-72.
Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ. Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. Breast J. 2014 Jul;20(4):358-63.   PMCID: 4472437
Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, Radice P, Ramus SJ, Domchek SM, Nathanson KL, Lee A, Healey S, Nussbaum RL, Rebbeck TR, Arun BK, James P, Karlan BY, Lester J, Cass I, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, v OH, Ejlertsen B, Gerdes AM, Nielsen FC, Dennis J, Cunningham J, Hart S, Slager S, Osorio A, Benitez J, Duran M, Weitzel JN, Tafur I, Hander M, Peterlongo P, Manoukian S, Peissel B, Roversi G, Scuvera G, Bonanni B, Mariani P, Volorio S, Dolcetti R, Varesco L, Papi L, Tibiletti MG, Giannini G, Fostira F, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Douglas F, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Ellis S, Godwin AK, Rhiem K, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Steinemann D, Bogdanova-Markov N, Kast K, Varon-Mateeva R, Wang-Gohrke S, Gehrig A, Markiefka B, Buecher B, Lefol C, Stoppa-Lyonnet D, Rouleau E, Prieur F, Damiola F, Barjhoux L, Faivre L, Longy M, Sevenet N, Sinilnikova OM, Mazoyer S, Bonadona V, Caux-Moncoutier V, Isaacs C, Van Maerken T, Claes K, Piedmonte M, Andrews L, Hays J, Rodriguez GC, Caldes T, de la Hoya M, Khan S, Hogervorst FB, Aalfs CM, de Lange JL, Meijers-Heijboer HE, van der Hout AH, Wijnen JT, van Roozendaal KE, Mensenkamp AR, van den Ouweland AM, van Deurzen CH, van der Luijt RB, Olah E, Diez O, Lazaro C, Blanco I, Teule A, Menendez M, Jakubowska A, Lubinski J, Cybulski C, Gronwald J, Jaworska-Bieniek K, Durda K, Arason A, Maugard C, Soucy P, Montagna M, Agata S, Teixeira MR, Olswold C, Lindor N, Pankratz VS, Hallberg E, Wang X, Szabo CI, Vijai J, Jacobs L, Corines M, Lincoln A, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Mai PL, Greene MH, Rennert G, Imyanitov EN, Glendon G, Toland AE, Bojesen A, Pedersen IS, Jensen UB, Caligo MA, Friedman E, Berger R, Laitman Y, Rantala J, Arver B, Loman N, Borg A, Ehrencrona H, Olopade OI, Simard J, Easton DF, Chenevix-Trench G, Offit K, Couch FJ, Antoniou AC. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014 Jan;16(6):3416.   PMCID: PMC4406179
Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM, June CH, Zhang PJ. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat. 2012 Jun;133(2):799-804.
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical Cancer Research. 2010 Mar 15;16(6):1904-14.   PMCID: NIHMS352308
Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. Journal of Clinical Oncology. 2008 May 20;26(15):2473-81.
Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Molecular cancer research : MCR. 2007 Jan;5(1):71-85.
Jordan VC, Gelber RD. Problems with the progesterone receptor in practice?. J Clin Oncol. 2007 May 20;25(15):1957-9.
Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1863-70.
Nunez MI, Rosen DG, Ludes-Meyers JH, Abba MC, Kil H, Page R, Klein-Szanto AJ, Godwin AK, Liu J, Mills GB, Aldaz CM. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC cancer. 2005 Jan;5(1):64.
Russo J, Lareef H, Tahin Q, Russo IH. Pathways of carcinogenesis and prevention in the human breast. Eur J Cancer. 2002 Sep;38 Suppl 6:31-2.
Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dube MP, Kieback DG, Narod SA. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001 Oct;11(7):635-8.
Logginidou H, Ao X, Russo I, Henske EP. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest. 2000 Jan;117(1):25-30.
Russo J, Hu YF, Yang X, Russo IH. Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr. 2000 Jan;(27):17-37.
Henske EP, Ao X, Short MP, Greenberg R, Neumann HP, Kwiatkowski DJ, Russo I. Frequent progesterone receptor immunoreactivity in tuberous sclerosis-associated renal angiomyolipomas. Mod Pathol. 1998 Jul;11(7):665-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Progesterone Receptors

Progesterone Receptors Female Estrogen Receptors Breast Neoplasms metabolism pathology Adult Middle Aged genetics Human therapeutic use therapy Ductal Carcinoma-Breast BRCA1 Genes erbB-2 Receptor Estrogens Lobular Carcinoma Neoplasm Staging physiology Immunoenzyme Techniques Genetic Predisposition to Disease Aged ErbB-2 Receptor Risk Factors Middle Age etiology BRCA2 Genes Mutation Age Factors drug therapy Retrospective Studies Carcinoma Treatment Outcome Prospective Studies diagnosis Hormone-Dependent Neoplasms Epidermal Growth Factor Receptor Cell Division pharmacology Kidney Neoplasms Neoplastic Gene Expression Regulation US Gov't Support-PHS Disease-Free Survival Male 80 and over Aged Lymphatic Metastasis Postmenopause Non-US Gov't Support Heterozygote Ovarian Neoplasms secondary Survival Rate Alleles Local Neoplasm Recurrence Time Factors Angiomyolipoma Oral Contraceptives Tamoxifen Multiple Primary Neoplasms GPI-Linked Proteins Prognosis Breast Cultured Tumor Cells Case-Control Studies Male Breast Neoplasms Proto-Oncogene Proteins c-akt Antineoplastic Agents Residual Neoplasm molecular subtype Triazoles T-Lymphocytes United States Gel Electrophoresis-Two-Dimensional immunology Antineoplastic Combined Chemotherapy Protocols Tumor Suppressor Genes Segmental Mastectomy Lung Neoplasms Abdominal Neoplasms Antineoplastic Combined Chemotherapy Adjuvant Chemotherapy Ovary Estrogen Antagonists Genetic Models Genetic Transcription Nitriles Tumor Suppressor Proteins Germ-Line Mutation Neoplasm Antigens anatomy & histology epidemiology Biopsy Western Blotting Immunotherapy receptor status Epithelial Cells Electrophoretic Mobility Shift Assay Questionnaires surgery Lymphangiomyomatosis Oxidoreductases Presenilin-2 Oligonucleotide Array Sequence Analysis Immunohistochemistry Canada pharmacokinetics Delayed Diagnosis Biological Tumor Markers utilization Signal Transduction Mitogen-Activated Protein Kinase Kinases Carcinoma in Situ Genetic Transduction Australia administration & dosage Lymph Node Excision Tissue Distribution Neoplasm Grading Gene Deletion Logistic Models prevention & control Axilla breast cancer axillary lymph nodes DNA Replication deficiency Registries Tuberous Sclerosis Tumor Cell Line Protocols Loss of Heterozygosity Trinidad and Tobago Messenger RNA Response Elements Sentinel Lymph Node Biopsy growth & development Reverse Transcriptase Polymerase Chain Reaction Homozygote biosynthesis Cell Differentiation Promoter Regions (Genetics) Menopause drug effects Heterozygote Detection Estradiol analysis Combined Modality Therapy Neoplasm Metastasis Transformed Cell Line Phosphorylation
Last updated on Friday, January 03, 2020